Camp4 CFO Kelly Gold buys $39,600 in company stock
Camp4 Therapeutics CFO Kelly Gold made a stock purchase of $39,600 on August 31, 2026. She acquired 10,000 shares of the company's common stock through multiple open market transactions, with a weighted average price of $3.96 per share. The stock had experienced a roughly 8% decline over the past week, but remained up by 170% over the past year.
Ms. Gold, whose spouse, David Gold, holds these shares in a brokerage account, indicated she does not have investment control over the account and disclaims beneficial ownership. Analysts at InvestingPro view the stock as potentially undervalued, suggesting the stock could be a promising investment. Recently, CAMP4 Therapeutics has garnered attention from analysts, with JPMorgan upgrading the stock to Overweight and raising its price target to $9.00.
Chardan also initiated coverage on the stock with a buy rating and a price target of $6.50. In addition, Kelly Gold has been appointed to the board of directors for X4 Pharmaceuticals, where she will also serve on the audit committee. These moves showcase strategic developments within both companies.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
